About Guangbin Luo

Dr. Luo graduated in Molecular Genetics in 1993 from the University of
Illinois at Urbana-Champaign. He became a postdoctoral fellow at
University of Texas MD Anderson Cancer Center in 1993, and then a
Research Associate in Dr. Allan Bradley at the Howard Hughes Medical
Institute at Baylor College of Medicine in 1996.

He is the recipients
of the Howard Temin Award from the National Cancer Institute in 2000,
the Basil O'Connor Starter Scholar Award from the March of Dimes
Foundation in 2001, and the Searle Scholar Award in 2001.

He has
served as an Associate Editor for the journal of Current Genomics
since 1999.

Dr. Luo joined the Department of Genetics and the Ireland
Cancer Center at CWRU and University Hospitals of Cleveland in May,
2000.

Research

My laboratory use mouse to model human diseases and to conduct
other aspect of genetic studies, including gene identification.

We are
currently using knockout mouse models to study a unique class of human
syndromes that are caused by mutations in RecQ DNA helicase
homologues.

Defects in RecQ DNA helicase homologues in these human
syndromes have led to genomic instability and cancer predisposition
and a great variety of other abnormalities.

We are particularly
interested in studying how defects in individual RecQ helicase can
lead to specific disease phenotypes in these distinct yet similar
syndromes. A mouse model for both Bloom and Rothmund-Thomson syndromes
are now being studied in the laboratory.

We are also continuing to
further develop the Sleeping Beauty (SB) transposon as an insertional
mutagen for mouse genetic study. The SB transposon is the only known
active DNA transposon in mice. We are currently using this transposon
system to set up transposon-tagged mutagenesis strategies for
phenotype-driven genetic screens in mice to identify novel candidates
genes for cancer as well as other human
diseases.

Selected Publications

Hu Y, Lu X, Zhou G, Barnes EL, Luo G (2008)

Recql5 Plays an Important Role in DNA Replication and Cell Survival Following Camptothecin Treatment.